VISTA inhibitors Drugs Clinical Trials FDA Approval Market Opportunity Insight

Global VISTA Inhibitor Clinical Trials and Market Opportunity Insight 2024 Report Highlights:

• Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
• VISTA Inhibitors Clinical Trials: 8 Drugs
• US Dominating VISTA Inhibitors Clinical Trials Landscape: 5 Drugs
• Global VISTA Inhibitors Market Trends and Clinical Innovation
• Competitive Landscape: Insight On 10 Companies
• Future Clinical and Commercialization Opportunities

Download Report:

https://www.kuickresearch.com/report-visti-inhibitors-clinical-trials-vista-inhibitors-antibody-vista-checkpoint-inhibition-vista-inhibitors-cancer-immunotherapy--vista-expression

The field of immunotherapy in the fight against cancer has long been regarded as an essential tool in the therapeutic landscape. Powered by its high safety and efficacy, immunotherapy has become a prominent therapeutic strategy utilized not only for cancer but also for several other ailments. Strategies such as immune checkpoint blockers or inhibitors, which modulate the body's immune response, such as PD-1/PD-L1 and CTLA-4, have revolutionized cancer treatment, leading to a robust patient response and skyrocketing commercial success in recent years. However, there remains considerable room for development.

Although immune checkpoint blockers have played a significant role in the rise of immunotherapy within cancer treatment, their effectiveness has been limited to a relatively small number of patients, creating a substantial unmet need. Immune checkpoints can have either stimulatory functions that promote immune cell activation or inhibitory functions that suppress this activation. Recently, researchers have shifted their focus to exploiting the stimulatory functions of immune checkpoints. One noteworthy discovery in this area is the V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) checkpoint, which plays a critical role in T cell and lymphocyte proliferation as well as cytokine production.

Further studies on VISTA, also known as PD-1H, C10orf54, VSIR, B7-H5, DD1α, Gi24, or Dies1, illustrate its role as a co-inhibitory checkpoint expressed on hematopoietic cells, myeloid cells, and T cells. Therefore, the development of inhibitors or small molecules targeting the VISTA checkpoint could help reduce the risk and progression of cancer. Moreover, developing novel VISTA inhibitors presents several advantages, as anti-VISTA clones can enhance or diminish both innate and adaptive immune responses in patients suffering from cancer and autoimmune diseases.

To substantiate this hypothesis, multiple studies are underway with the primary aim of developing advanced VISTA inhibitors. For example, CA-170, an inhibitor targeting the immune checkpoints VISTA and programmed death ligands 1 and 2 (PD-L1/PD-L2), represents a treatment regimen for patients with advanced solid tumors or lymphomas. This clinical study is currently in Phase I and is sponsored in collaboration with Curis. Furthermore, to assess the safety and efficacy of CA-170, the inhibitor is being evaluated in various indications, including mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple-negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer, with the objective of understanding its overall efficacy.

The pipeline for VISTA inhibitors has introduced numerous novel candidates into the field, with estimates suggesting that over 70 candidates have been added recently. Scientists and researchers are rigorously evaluating the effectiveness of these new VISTA contenders alongside other immune checkpoint inhibitors to enhance and maximize therapeutic activity. For instance, HMBD-002, a novel monoclonal antibody (mAb) that suppresses the VISTA receptor, is being investigated in combination with Pembrolizumab, a mAb that inhibits PD-L1 and PD-L2. This combination regimen is aimed at treating patients with various cancer types, including non-small cell lung cancer, triple-negative breast cancer, malignant neoplasm, metastatic cancer, and advanced solid tumor indications. The study is currently in Phase I, sponsored in collaboration with Hummingbird Bioscience and Merck Sharp & Dohme LLC.

Additionally, various centers, hospitals, and universities, such as the Southern California Research Center, Cedars-Sinai Medical Center, Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, and Advanced Cardiovascular, LLC, are conducting numerous clinical trials with the goal of developing novel VISTA inhibitors for a range of indications, including lung cancer, renal cell carcinoma, melanoma, gastric cancer, endometrial cancer, and mesothelioma. All of these aspects illustrate that the market for VISTA inhibitors is growing at an incredible pace and will continue to expand, especially once the first commercial inhibitor receives approval from the FDA.

KuicK Research
Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.